Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBX-100 in healthy volunteers
NCT07399899Phase 1Not yet recruiting
- Sponsor
- Neuraly
- Start
- Jan 2026
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of N,N-dimethyltryptamine + harmala, sponsored by Neuraly. Primary endpoints: Area under the plasma concentration versus time curve (last) at 24 hours, Area under the plasma concentration versus time curve (zero to infinity) at 24 hours and 4 more. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
N,N-dimethyltryptamine + harmala
Beyond the preview
Go deeper on NCT07399899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07399899.